Robert Sambursky | President and Chief Executive Officer
Rapid Pathogen Screening, Inc (RPS)

Robert Sambursky, President and Chief Executive Officer, Rapid Pathogen Screening, Inc (RPS)

Robert Sambursky, MD is one of the original founders of RPS Diagnostics, and has served various roles including Chief Executive Officer from July 2012 until June 2017, President since 2010, and Chief Medical Officer since 2008. He is an inaugural member of both the Leadership Team and Board of Directors. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology, and infectious disease. He conceived numerous patents, developed a point-of-care (POC) diagnostic platform, designed clinical protocols, and served as the regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as both U.S. FDA 510(k) clearance and CLIA waiver designations. Further, Dr. Sambursky was responsible for all medical affairs activities including development of key opinion leaders (KOLs), clinical marketing and product training, and creating a successful reimbursement strategy that lead to the issuance of dedicated U.S. Medicare CPT codes.

Currently Dr. Sambursky continues to serve as President as well as Chief Technology and Medical Officer where his leadership responsibilities include strategic planning and business development, oversight of innovation, research and new product development, and leading clinical and regulatory affairs, KOL development, health policy and government affairs, reimbursement, and evidence based marketing. He is considered a subject area expert and serves as a global spokesperson.

In addition, Dr. Sambursky is a practicing, board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He currently sits on several ophthalmic pharmaceutical advisory boards, serves as an editorial consultant to several professional organizations and publications, is a member of the Vanguard Ophthalmology Society, and has co-authored numerous articles in medical journals. He currently serves as a consultant for Quidel Corp. Dr. Sambursky earned his BA in Biology from Brown University, MA in Medical Sciences with a concentration in biochemistry and microbiology from Boston University, and MD from Boston University School of Medicine. He completed his medical internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.


World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 11:50

FebriDx: A rapid Point of Care (POC) Test for the Simultaneous Detection of MxA and CRP to support outpatient antibiotic stewardship

  • Identifying viral and bacterial infections through a combination of MxA and CRP biomarkers
  • Review of prospective, multi-center clinical trial and outcome study data
  • Supporting outpatient antibiotic stewardship through cost effective FebriDx testing
last published: 16/Oct/18 20:05 GMT

back to speakers